September 28, 2022
Life Sciences
  • The U.S. Food and Drug Administration (FDA) said it will now review only a small number of emergency use authorization (EUA) requests for COVID-19 tests. Companies that request EUAs for their tests will have to demonstrate the tests are likely to have a significant benefit to public health and fulfill an unmet need; they will also have to apply via the FDA’s traditional premarket review process. The agency made the revision in light of the current manufacturing status and number of cases. (Article here)